Characterization of a new low‐dose 6‐hydroxydopamine model of Parkinson's disease in rat
暂无分享,去创建一个
Anna-Maija Penttinen | Merja H Voutilainen | Mikko Airavaara | Ilida Suleymanova | M. Airavaara | J. Anttila | Katrina Albert | Jenni Anttila | Katrina Albert | M. Voutilainen | A. Penttinen | I. Suleymanova
[1] Y. Agid,et al. Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra , 1996, Brain Research.
[2] Y. Michotte,et al. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line‐derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model , 2009, The journal of gene medicine.
[3] R. Burke,et al. Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat , 2002, Brain Research.
[4] J. O'Brien,et al. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. , 2012, Brain : a journal of neurology.
[5] A. Granholm,et al. 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat , 1996, Experimental Brain Research.
[6] G. Wooten,et al. Altered pharmacokinetics of L‐dopa metabolism in rat striatum deprived of dopaminergic innervation , 1984, Neurology.
[7] P. Tuomainen,et al. Different in vivo properties of three new inhibitors of catechol O‐methyltransferase in the rat , 1992, British journal of pharmacology.
[8] U. Ungerstedt,et al. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.
[9] Greg A. Gerhardt,et al. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats , 1993, Brain Research.
[10] L. Swanson. The Rat Brain in Stereotaxic Coordinates, George Paxinos, Charles Watson (Eds.). Academic Press, San Diego, CA (1982), vii + 153, $35.00, ISBN: 0 125 47620 5 , 1984 .
[11] M. Saarma,et al. Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's Disease , 2009, The Journal of Neuroscience.
[12] A. Salgado,et al. Behavioral characterization of the 6-hydroxidopamine model of Parkinson’s disease and pharmacological rescuing of non-motor deficits , 2013, Molecular Neurodegeneration.
[13] A. Björklund,et al. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat , 1996, Neuroscience.
[14] D. Togasaki,et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamine , 1995, Neuroscience.
[15] Anders Björklund,et al. Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat , 1998, Experimental Neurology.
[16] Y. Agid,et al. Injection of 6-hydroxydopamine into the substantia nigra of the rat. II. Diffusion and specificity. , 1973, Brain research.
[17] T. Robinson,et al. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis , 1986, Brain Research Reviews.
[18] L. Butcher. Degenerative processes after punctate intracerebral administration of 6-hydroxydopamine , 2005, Journal of Neural Transmission.
[19] A. Herbet,et al. Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system , 1976, Brain Research.
[20] R. Faull,et al. Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra. , 1969, Experimental neurology.
[21] T. Robinson,et al. Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[22] Jos Prickaerts,et al. Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway , 2002, Experimental Neurology.
[23] R. Burke,et al. Clinical progression in Parkinson disease and the neurobiology of axons , 2010, Annals of neurology.
[24] K. Soliman,et al. The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro , 2004, Brain Research.
[25] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[26] A. Björklund,et al. Studies on Neuroprotective and Regenerative Effects of GDNF in a Partial Lesion Model of Parkinson's Disease , 1997, Neurobiology of Disease.
[27] L. Descarries,et al. Quantification of the dopamine innervation in adult rat neostriatum , 1986, Neuroscience.
[28] M. Saarma,et al. Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease , 2013, Brain and behavior.
[29] M. Horne,et al. Axonal sprouting following lesions of the rat substantia nigra , 2000, Neuroscience.
[30] D. C. Sterio. The unbiased estimation of number and sizes of arbitrary particles using the disector , 1984, Journal of microscopy.
[31] John L. Hudson,et al. Conditioned apomorphine-induced turning in 6-OHDA-lesioned rats , 1994, Pharmacology Biochemistry and Behavior.
[32] M. Saarma,et al. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease , 2011, Experimental Neurology.
[33] M. Youdim,et al. Mechanism of 6-hydroxydopamine neurotoxicity. , 1997, Journal of neural transmission. Supplementum.
[34] C. Cunha,et al. Induction of depressive-like behavior by intranigral 6-OHDA is directly correlated with deficits in striatal dopamine and hippocampal serotonin , 2014, Behavioural Brain Research.
[35] A. Raasmaja,et al. High correlation between in vivo [123I]β-CIT SPECT/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions induced by 6-OHDA in rats , 2013, EJNMMI Research.
[36] Mark J. West,et al. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias , 1999, Trends in Neurosciences.
[37] G. Nappi,et al. Time‐course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6‐hydroxydopamine in the rat: new clues from an old model , 2007, The European journal of neuroscience.
[38] R. Wurtman,et al. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization , 1980, Brain Research.
[39] Gwang Lee,et al. Formation of parkin aggregates and enhanced PINK1 accumulation during the pathogenesis of Parkinson's disease. , 2010, Biochemical and biophysical research communications.
[40] E. Abercrombie,et al. l‐3,4‐Dihydroxyphenylalanine‐Induced Dopamine Release in the Striatum of Intact and 6‐Hydroxydopamine‐Treated Rats: Differential Effects of Monoamine Oxidase A and B Inhibitors , 1994, Journal of neurochemistry.
[41] W. H. Oertel,et al. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.
[42] W. Pirker,et al. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts , 2014, Movement disorders : official journal of the Movement Disorder Society.
[43] S. Kish,et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.
[44] Robert E. Burke,et al. Axon degeneration in Parkinson's disease , 2013, Experimental Neurology.
[45] P. Kalivas,et al. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity , 1991, Brain Research Reviews.